Shots:

• The companies will advance the prasinezumab into a P-IIb study in patients with early Parkinson’s disease based on positive signals of efficacy consistent with disease modification in the PASADENA study
• The study is designed to further assess the efficacy of prasinezumab by expanding upon the patient population enrolled in PASADENA study to include patients with early Parkinson’s disease on stable levodopa therapy and is expected to initiate in 2021
• Prasinezumab is the first anti-alpha synuclein Ab to advance into late-stage development. Additionally- Prothena will earn a $60M clinical milestones upon the first patient dosed in the study

 ­ Ref: PRNewswire | Image: Roche